Ceftobiprole is a broad-spectrum cephalosporin with activity against Methicillin-resistant staphylococcus aureus (MRSA) with the MIC₉₀ value of 2 mcg/mL. IC50 & Target: MIC90: 2 mcg/mL (MRSA)^[1] In Vitro: Ceftobiprole has demonstrates activity against important gram-positive bacteria, including penicillin-resistant S. pneumonia (PRSP), Methicillin-resistant S. aureus (MRSA), and E. faecalis with MIC₉₀ values of 0.25, 2, and 2 mcg/mL, respectively. Ceftobiprole has also demonstrated potent in vitro activity against several clinical isolates of community-associated Methicillin-resistant S. aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), and Vancomycin-resistant S. aureus (VRSA), with a minimum inhibitory concentration (MIC) of 2 mcg/mL^[1]. Ceftobiprole is highly active against S. aureus, withMICs ranging from 0.12 to 4 mg/L (only one resistant strain,MIC of 4 mg/L). Furthermore, Ceftobiprole is twice more active on Methicillin-susceptible S. aureus (MSSA) strains with MIC₅₀ and MIC₉₀ of 0.5 mg/L than on MRSA strains with MIC₅₀ and MIC₉₀ of 1 mg/L. Moreover, Panton-Valentine leukocidin (PVL)+MRSA are slightly more susceptible to Ceftobiprole (MIC₅₀ of 0.5 mg/L and MIC₉₀ of 1 mg/L) than PVL-MRSA (MIC₅₀ and MIC₉₀ of 1 mg/L)^[2].